Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication

被引:30
|
作者
Zhang, Ya-Wen [1 ,2 ]
Hu, Wei-Ling [1 ,2 ]
Cai, Yuan [1 ]
Zheng, Wen-Fang [1 ,2 ]
Du, Qin [3 ]
Kim, John J. [4 ]
Kao, John Y. [5 ]
Dai, Ning [1 ]
Si, Jian-Min [1 ,2 ]
机构
[1] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Gastroenterol, 3 East Qingchun Rd, Hangzhou 310016, Zhejiang, Peoples R China
[2] Zhejiang Univ, Inst Gastroenterol, Hangzhou 310016, Zhejiang, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Gastroenterol, Hangzhou 310009, Zhejiang, Peoples R China
[4] Loma Linda Univ, Div Gastroenterol, Loma Linda, CA 92354 USA
[5] Univ Michigan, Dept Internal Med, Div Gastroenterol, Michigan Med, Ann Arbor, MI 48109 USA
关键词
Helicobacter pylori; Furazolidone; Quadruple regimen; Side effects; Eradication; TRIPLE THERAPY; BISMUTH; RESISTANCE; REGIMENS; GASTROENTEROLOGY; CLARITHROMYCIN; METAANALYSIS; RABEPRAZOLE; 1ST-LINE; EFFICACY;
D O I
10.3748/wjg.v24.i40.4596
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM To evaluate the outcomes of furazolidone- and amoxicillin-based quadruple therapy for treatment of Helicobacter pylori (H. pylori) infection and identify predictors of failed eradication. METHODS Patients with H. pylori infection treated with furazolidone, amoxicillin, bismuth, and proton pump inhibitor therapy (January 2015 to December 2015) who received the C-13-urea breath test > 4 wk after treatment were evaluated. Demographic and clinical data including prior H. pylori treatment attempts, medication adherence, alcohol and cigarette consumption during therapy, and treatment-related adverse events were recorded by reviewing medical records and telephone surveys. H. pylori eradication rates for overall and subgroups were evaluated. Multivariate analysis was performed to identify independent predictors of failed H. pylori eradication. RESULTS Of the 992 patients treated and retested for H. pylori infection, the overall eradication rate was 94.5% [95% confidence interval (CI): 94.1%-95.9%]. H. pylori eradication rate of primary therapy was 95.0% (95%CI: 93.5%-96.5%), while that of rescue therapy was 91.3% (95%CI: 86.8%-95.8%). Among the 859 patients who completed the study protocol, 144 (17%) reported treatment-related adverse events including 24 (3%) leading to premature discontinuation. On multivariate analysis, poor medication adherence [adjusted odds ratio (AOR) = 6.7, 95%CI: 2.8-15.8], two or more previous H. pylori treatments (AOR = 7.4, 95%CI: 2.2-24.9), alcohol consumption during therapy (AOR = 4.4, 95%CI: 1.5-12.3), and possibly smoking during therapy (AOR = 1.9, 95%CI: 0.9-4.3) were associated with failed H. pylori eradication. CONCLUSION Furazolidone- and amoxicillin-based quadruple therapy for H. pylori infection in an area with a high prevalence of clarithromycin resistance demonstrated high eradication rates as primary and rescue therapies with a favorable safety profile. Patient education targeting abstinence from alcohol during therapy and strict medication adherence may further optimize H. pylori eradication.
引用
收藏
页码:4596 / 4605
页数:10
相关论文
共 50 条
  • [11] Effect of Dosing Schemes of Amoxicillin on Eradication Rates of Helicobacter pylori With Amoxicillin-Based Triple Therapy
    Furuta, Takahisa
    Sugimoto, Mitsushige
    Yamade, Mihoko
    Uotani, Takahiro
    Sahara, Shu
    Ichikawa, Hitomi
    Yamada, Takanori
    Osawa, Satoshi
    Sugimoto, Ken
    Watanabe, Hiroshi
    Umemura, Kazuo
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (03): : 258 - 266
  • [12] A modified Bismuth-Containing Quadruple Therapy Including a Short Course of Furazolidone for Helicobacter pylori Eradication After Sequential Therapy Failure
    Fakheri, Hafez
    Bari, Zohreh
    Sardarian, Hossein
    HELICOBACTER, 2012, 17 (04) : 264 - 268
  • [13] Furazolidone-Based Quadruple Therapy for Eradication of Helicobacter pylori Infection in Peptic Ulcer Disease
    Jahromi, Rahim Raoufi
    Mirzaei, Jamal
    Rajabi, Jalil
    Shokouh, Seyed Javad Hoseini
    Liaghat, Taraneh
    ARCHIVES OF CLINICAL INFECTIOUS DISEASES, 2014, 9 (03):
  • [14] Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures
    Treiber, G
    Ammon, S
    Malfertheiner, P
    Klotz, U
    HELICOBACTER, 2002, 7 (04) : 225 - 231
  • [15] Quadruple therapy for eradication of Helicobacter pylori
    Ma, Hai-Jun
    Wang, Jin-Liang
    WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (06) : 931 - 935
  • [16] Furazolidone-based triple and quadruple eradication therapy for H. pylori infection
    Lv, Nonghua
    Xie, Yong
    Chen, Ye
    Wang, Jiangbin
    Liu, Wenzhong
    Zhang, Zhenyu
    Wang, Weihong
    Du, Yiqi
    Xu, Jianming
    Zhang, Guiying
    Huo, Lijuan
    Wang, Xuehong
    Li, Xiaoyan
    Lan, Chunhui
    Li, Yanqing
    Wang, Hong
    Zhang, Guoxin
    Lv, Zhifa
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 15 - 15
  • [17] Tetracycline- and Furazolidone-containing Quadruple Regimen as Rescue Treatment for Helicobacter pylori Infection: A Single Center Retrospective Study
    Zhang, Yuemiao
    Gao, Wen
    Cheng, Hong
    Zhang, Xuezhi
    Hu, Fulian
    HELICOBACTER, 2014, 19 (05) : 382 - 386
  • [18] Quadruple therapy for eradication of Helicobacter pylori
    Hai-Jun Ma
    Jin-Liang Wang
    World Journal of Gastroenterology, 2013, (06) : 931 - 935
  • [19] Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Helicobacter pylori infection
    Bang, Chang Seok
    Lim, Hyun
    Jeong, Hae Min
    Shin, Woon Geon
    Choi, Jae Ho
    Soh, Jae Seung
    Kang, Ho Suk
    Yang, Young Joo
    Hong, Ji Taek
    Shin, Suk Pyo
    Suk, Ki Tae
    Lee, Jae Jun
    Baik, Gwang Ho
    Kim, Dong Joon
    GUT MICROBES, 2020, 11 (05) : 1314 - 1323
  • [20] Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication
    Chang, Young Woon
    Shin, Ga Young
    Kim, Jung-Wook
    Moon, Jin-Chang
    Chang, Eun Jee
    Oh, Chi Hyuk
    Jang, Jae-Young
    DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (04) : 1222 - 1230